Targeting cld18.2 positive patients with new cancer drug, TORL-2-307-ADC in patients with advanced cancer. This is a phase 1 study and UCLA Dr. Zev Wainberg, Santa Monica is conducting this research study. It's a 2 part study with part 1 it's given as a single agent. In part 2, the MTD (maximum tolerated dose) will be determined. It's for those with advanced gastric or gastroesophageal cancer. 30 participants in phase 1 and up to 80 in phase 2.
They are recruiting now so if interested give dr Wainberg a call. Please post if you decide to try this trial and wishing the best for you. I'll post if I find a clinical trial that I qualify for.

By the way did you know there are certain mutations associated with peritoneal cancer? I repeated my blood biopsy or the Guardant 360 test and a new mutation has been found: SMAD4 which I read is associated with peritoneal cancer and just another mutation along with the others I have KRAS12D, TP53, ATM(VUS) to make fighting this disease that much more difficult as it is resistant to chemo and radiation. Thank goodness I had histotripsy instead of the targeted radiation! I'm trying gem-abraxane once again, but I'm not ignorant to the fact that because of SMAD4, it might not work this time so I am fervently looking for trials that look promising to me that I might qualify for.